Skip to main content
Fig. 7 | Stem Cell Research & Therapy

Fig. 7

From: Synergism of MSC-secreted HGF and VEGF in stabilising endothelial barrier function upon lipopolysaccharide stimulation via the Rac1 pathway

Fig. 7

MSC-secreted VEGF and HGF upregulated Rac1 activity (Fig. 7a and b) and downregulated RhoA activity (Fig.7a and c) in LPS-stimulated HPMECs. MSC-CM treatment upregulated Rac1 activity and downregulated RhoA activity in LPS-stimulated HPMECs. However, the effect of MSCs was significantly inhibited by neutralising HGF or both VEGF and HGF from the MSC-CM with HGF antibody or both VEGF and HGF antibodies. Neutralising VEGF from the MSC-CM with anti-VEGF did not affect the effect of MSCs. Adding MSC-CM in all groups except control group and LPS group. n = 3, *p < 0.05; **p < 0.01 vs. control group; # p < 0.05 vs. LPS group; &p < 0.05; &&p < 0.01 vs. MSC-CM group. CM Conditioned medium, HGF Hepatocyte growth factor, LPS Lipopolysaccharide, MSC Mesenchymal stem cell, VEGF Vascular endothelial growth factor

Back to article page